Physician profile
Sarah A Parrish
NPI 1922268523
$1,327.10
in general payments reported to CMS, 2019-2025
21 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $179 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.83 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $228.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $216.21 | 2025 | |
| Axsome Therapeutics, INC. | $101.71 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.80 | 2024-2025 | Caplyta |
| Insulet Corporation | $98.06 | 2024-2025 | Omnipod |
| Glaxosmithkline, LLC. | $71.65 | 2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $64.03 | 2024-2025 | |
| Exact Sciences Corporation | $61.68 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $54.76 | 2025 | Synchromedii |
| Pfizer INC. | $45.52 | 2024-2025 | |
| Amgen INC. | $43.37 | 2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $40.51 | 2024-2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $34.11 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $33.14 | 2025 | Heplisav-B |
| Lilly USA, LLC | $29.98 | 2025 | Mounjaro, Zepbound |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.36 | 2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $19.12 | 2025 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $18.51 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $17.87 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $16.49 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.26 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.